Obesity expert reveals the best way to decide if GLP-1s are right for youObesity expert reveals the best way to decide if GLP-1s are right for you
Some experts believe that anyone could benefit from GLP-1 medications, as the popular drugs have become more widespread and accessible. Others, however, warn that the decision to take the diabetes and weight-loss drugs should be based on health history and potential risks. So, how do you know if you’re a good candidate? In an interview Read More
Ozempic is changing the foods Americans buyOzempic is changing the foods Americans buy
When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new research, the medications are associated with meaningful reductions in how much households spend on food, both at the grocery store and at restaurants. When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the Read More
Study finds more comfortable option for guiding breast cancer surgeryStudy finds more comfortable option for guiding breast cancer surgery
A new study led by researchers at Wake Forest University School of Medicine and Atrium Health Levine Cancer has found that a modern technique for locating breast tumors before surgery, called radioactive seed localization (RSL), is just as effective as the traditional wire localization (WL) method, while offering patients and surgeons a better overall experience.
I’m a Doctor Who Tried GLP-1 Drugs. Here’s How They Changed My Life.I’m a Doctor Who Tried GLP-1 Drugs. Here’s How They Changed My Life.
(MedPage Today) — In this video, Mikhail Varshavski, DO, who goes by “Dr. Mike,” talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine. Following is a partial transcript… (MedPage Today) — In this video, Mikhail Varshavski, DO, who goes by “Dr. Mike,” Read More
For Black women with breast cancer, ultra-processed foods may worsen health outcomesFor Black women with breast cancer, ultra-processed foods may worsen health outcomes
A study by Rutgers Cancer Institute researchers is the first to link ultra-processed foods to reduced survival in Black women with breast cancer.
Establishing Connection and Trust With Breast Cancer PatientsEstablishing Connection and Trust With Breast Cancer Patients
(MedPage Today) — In “Beyond Diagnosis: Breast Cancer,” Cleveland Clinic oncologist Tiffany Onger, MD, and host John Mangels discuss the dynamics of communicating effectively and empathetically with patients facing the challenges of this life…
Can you get addicted to a GLP-1?Can you get addicted to a GLP-1?
Model Brooks Nader calls these drugs a “crutch.” Model Brooks Nader calls these drugs a “crutch.”
Alcohol Consumption and Breast Cancer RiskAlcohol Consumption and Breast Cancer Risk
(MedPage Today) — Multiple studies have linked alcohol consumption to an increased risk of breast cancer, and binge drinking may exacerbate that risk.
“There’s indeed overwhelming evidence that consuming alcohol is associated with an increased…
Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, is likely a factor. Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates Read More
Tirzepatide Matches Competitor’s Cardioprotective Benefits for DiabeticsTirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large… (MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) Read More